“What if getting a new therapy to patients could happen months faster?
Right now, starting a clinical trial in the U.S. takes much longer than in other countries, which means patients sometimes have to travel overseas just to access investigational treatments.
To address this, the FDA is piloting a new approach called the Expedited IND Program, which brings in specialized research institutions to work alongside drug developers earlier in the process. Think of it like adding an expert co-pilot to help navigate the path to clinical trials so issues get caught and resolved sooner, and promising therapies reach patients faster.
Want to learn more or share your perspective? Join our free stakeholder webinar on Aug. 6 and check out our Request for Information.”